Ra Pharma’s Cyclomimetic Technology To Help Merck With Difficult Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
In its first partnership, Ra, focused on solutions for intracellular protein-protein reactions, could earn up to $200 million by helping Merck to discover and develop drug candidates for protein targets in several undisclosed therapeutic areas.
You may also be interested in...
Ra Pharma Aims For Oral Peptide Drugs Using Synthetic Amino Acids
Just out of stealth mode, privately held biotech closes second tranche of $27 million Series A financing and announces first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.